Sino Biopharmaceutical Limited Announces That Application for Clinical Trial of "TQC2938" Injection, A Category I New Drug Self-Developed by the Group, Has Been Submitted to and Accepted by the National Medical Products Administration of China

The board of directors of Sino Biopharmaceutical Limited announced that application for clinical trial of "TQC2938" injection, a Category I new drug self-developed by the Group, has been submitted to and accepted by the National
Medical Products Administration of China. TQC2938 injection is an innovative monoclonal antibody product targeting respiratory diseases. TQC2938 is a highly active blocking antibody that reduces the production of downstream Th2 cytokines and decreases the level of inflammatory cells. Preclinical animal efficacy tests show that TQC2938 can significantly improve disease symptoms.